EUCTR2018-002680-26-ES进行中（未招募）1 期
Gene Therapy for Leukocyte Adhesion Deficiency-I (LAD-I): A Phase I Clinical Trial to Evaluate the Safety and Efficacy of the Infusion of Autologous Hematopoietic Stem Cells Transduced with a Lentiviral Vector Encoding the ITGB2 Gene
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 2
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. A confirmed diagnosis of severe LAD-I as demonstrated by flow cytometry indicating CD18 expression on <2% neutrophils (polymorphonuclear neutrohils [PMNs]). (Patients in which CD18+ PMNs are >2% will be considered eligible with <2% CD11a or CD11b expressing PMNs and if there is a documented ITGB2 mutation and clinical history consistent with LAD-I (or known family history).
- •2. At least one (1) prior significant bacterial or fungal infection (US National Cancer Institute [NCI] Common Terminology Criteria for Adverse Events [CTCAE], v5.0, Grade greater than or equal 2). This criteria is not required for patients with documented family history who meet the above inclusion criteria.
- •3. Age greater than or equal 3 months.
- •4. Considered to be an appropriate candidate for autologous transplantation of HSCs.
- •5. A competent custodial parent with legal capacity to execute an EC-approved consent form must be available to participate in the consent process. (Informed assent will be sought from capable patients, in accordance with the directive of the EC and with local requirements.)
- •6. Ability to comply with trial procedures including investigational therapy and follow-up evaluations.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 2
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Availability of a medically-eligible human leukocycte antigen (HLA)-identical sibling donor transplant. Patients may not be included in this trial as an alternative to a clinically-indicated and feasible HLA-matched sibling donor HSC transplant. If an HLA-identical sibling is identified, but mPB or BM HSC collection is not feasible (for example: donor is in utero, is a newborn from whom cord blood was not collected, or is unable to undergo donation procedure because of medical impairments), then inclusion may be permitted per the Principal Investigator discretion.
- •2. Hepatic dysfunction as defined by either:
- •Bilirubin > 1.5 × the upper limit of normal (ULN) or
- •Alanine aminotransferase (ALT) or asparate aminotransferase (AST) >2.5×ULN
- •3. Renal dysfunction as defined by either Grade 3 or higher abnormalities in serum sodium, potassium, calcium, magnesium or phosphate as defined by NCI CTCAE v5.0, or the requirement for either peritoneal dialysis or hemodialysis.
- •4. Pulmonary dysfunction as defined by either:
- •Need for supplemental oxygen during the prior 2 weeks (in absence of acute infection).
- •Oxygen saturation (by pulse oximetry) <90%.
- •5. Evidence of active metastatic or locoregionally advanced malignancy (including hematologic malignancy) for which survival is anticipated to be less than 3 years.
- •6. Serious infections with persistent bloodstream pathogens at time of trial entry. (Patients with active infections [e.g., unresolved ulcerative lesions, skin or oral infections] are permitted as long as appropriate antibiotic therapy has been [or is being] administered).
- •7. Any medical or other contraindication for both leukopheresis and BM harvest procedure, as determined by the treating investigator.
- •8. Any medical or other contraindication for the administration of conditioning therapy, as determined by the treating investigator.
- •9. Significant medical conditions, including documented human immunodeficiency virus (HIV) infection, poorly-controlled diabetes, poorly-controlled hypertension, poorly-controlled cardiac arrhythmia or congestive heart failure; or arterial thromboembolic events (including stroke or myocardial infarction) within the 6 prior months.
- •10. Any medical or psychiatric condition that in the opinion of the Investigator renders the patient unfit for trial participation or at higher than acceptable risk for participation.
研究者
相似试验
进行中（未招募）
1 期
Gene Therapy for Leukocyte Adhesion Deficiency-I (LAD-I):A Phase I/II Clinical Trial to Evaluate the Safety and Efficacy of the Infusion of Autologous Hematopoietic Stem Cells Transduced with a Lentiviral Vector Encoding the ITGB2 Geneeukocyte Adhesion Deficiency-I (LAD-I)MedDRA version: 20.0Level: LLTClassification code 10018137Term: Genetic anomalies of leukocytesSystem Organ Class: 100000004850EUCTR2020-000517-33-GBRocket Pharmaceuticals, Inc.9
已完成
1 期
A Clinical Trial to Evaluate the Safety and Efficacy of RP-L201 in Subjects With Leukocyte Adhesion Deficiency-ILeukocyte Adhesion Defect - Type INCT03812263Rocket Pharmaceuticals Inc.9
撤回
1 期
A Gene Therapy Trial to Evaluate the Safety and Efficacy of RP-L201 in Subjects With Leukocyte Adhesion Deficiency-ILeukocyte Adhesion Defect - Type INCT03825783Rocket Pharmaceuticals Inc.
进行中（未招募）
不适用
Long-Term Follow-Up (LTFU) for Gene Therapy of Leukocyte Adhesion Deficiency-I (LAD-I)Leukocyte Adhesion DeficiencyNCT06282432Rocket Pharmaceuticals Inc.9
已完成
2 期
Stem Cell Transplantation to Treat Leukocyte Adhesion DeficiencyLeukocyte-Adhesion Deficiency SyndromeNCT00031005National Institute of Allergy and Infectious Diseases (NIAID)10